CG Oncology (NASDAQ:CGON) Director Leonard Post Sells 1,000 Shares

CG Oncology, Inc. (NASDAQ:CGON) Director Leonard Post sold 1,000 shares of the business’s stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $74.54, for a total value of $74,540.00. Following the transaction, the director directly owned 1,000 shares of the company’s stock, valued at $74,540. The trade was a 50.00% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

CG Oncology Price Performance

Shares of CG Oncology stock opened at $76.29 on Wednesday. CG Oncology, Inc. has a 1 year low of $24.85 and a 1 year high of $79.39. The firm has a market cap of $6.76 billion, a PE ratio of -28.36 and a beta of 0.23. The company has a 50 day simple moving average of $69.99 and a two-hundred day simple moving average of $65.07.

CG Oncology (NASDAQ:CGON) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.24). The firm had revenue of $1.16 million for the quarter, compared to analysts’ expectations of $0.36 million. CG Oncology had a negative net margin of 3,602.68% and a negative return on equity of 25.20%. As a group, research analysts anticipate that CG Oncology, Inc. will post -3.25 earnings per share for the current year.

Institutional Investors Weigh In On CG Oncology

Several institutional investors have recently added to or reduced their stakes in CGON. BlackRock Inc. purchased a new stake in CG Oncology in the 2nd quarter worth approximately $444,509,000. Wellington Management Group LLP increased its stake in shares of CG Oncology by 8.8% during the fourth quarter. Wellington Management Group LLP now owns 5,999,790 shares of the company’s stock valued at $249,111,000 after buying an additional 487,011 shares during the period. Price T Rowe Associates Inc. MD raised its holdings in shares of CG Oncology by 116.7% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,443,144 shares of the company’s stock valued at $142,961,000 after acquiring an additional 1,854,386 shares in the last quarter. State Street Corp raised its holdings in shares of CG Oncology by 46.4% during the fourth quarter. State Street Corp now owns 2,996,695 shares of the company’s stock valued at $124,423,000 after acquiring an additional 950,028 shares in the last quarter. Finally, Alliancebernstein L.P. lifted its stake in CG Oncology by 15.0% in the second quarter. Alliancebernstein L.P. now owns 2,164,214 shares of the company’s stock worth $56,270,000 after acquiring an additional 281,637 shares during the period. Hedge funds and other institutional investors own 26.56% of the company’s stock.

Wall Street Analyst Weigh In

CGON has been the topic of a number of analyst reports. JPMorgan Chase & Co. lifted their target price on shares of CG Oncology from $91.00 to $96.00 and gave the stock an “overweight” rating in a research report on Monday, May 11th. HC Wainwright reaffirmed a “buy” rating and set a $100.00 price objective on shares of CG Oncology in a research note on Wednesday, July 29th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CG Oncology in a research note on Friday, July 17th. Wedbush lifted their price objective on CG Oncology from $77.00 to $80.00 and gave the stock an “outperform” rating in a report on Monday, May 11th. Finally, Royal Bank Of Canada lowered their target price on CG Oncology from $81.00 to $79.00 and set an “outperform” rating for the company in a research note on Friday, August 7th. Eleven analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $83.18.

CG Oncology Company Profile

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.